Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer

Frank vom Dorp, Stephan Tschirdewahn, Christian Niedworok, Henning Reis, Hans Krause, Carsten Kempkensteffen, Jonas Busch, Gero Kramer, Shahrokh F. Shariat, P. Nyírády, Herbert Rübben, Tibor Szarvas

Research output: Contribution to journalArticle

9 Citations (Scopus)


Purpose: Blood levels of YKL-40 are elevated in various malignancies and other inflammatory diseases. Higher YKL-40 levels have consequently been shown to correlate with poor prognosis in several cancers. We investigated the prognostic value of circulating and tissue levels of YKL-40 in renal cell cancer. Materials and Methods: Preoperative YKL-40 serum/plasma levels were determined in 222 surgically treated patients with renal cell cancer and in 35 controls. Postoperative serum samples were analyzed in 19 of the 222 renal cell cancer cases. Gene expression levels were assessed in 101 renal cell cancer frozen tissue samples using quantitative real-time reverse transcriptase-polymerase chain reaction. Finally immunohistochemical analysis was done in 37 renal cell cancer cases to assess tissue localization of YKL-40. Results were correlated with clinicopathological and followup data. Results: YKL-40 serum but not tissue gene expression levels were higher in patients with renal cell cancer compared to controls (p = 0.050). Serum YKL-40 levels significantly increased following nephrectomy (p

Original languageEnglish
JournalJournal of Urology
Publication statusAccepted/In press - 2016



  • Carcinoma, renal cell
  • CHI3L1 protein, human
  • Kidney
  • Nephrectomy
  • Prognosis

ASJC Scopus subject areas

  • Urology

Cite this

vom Dorp, F., Tschirdewahn, S., Niedworok, C., Reis, H., Krause, H., Kempkensteffen, C., Busch, J., Kramer, G., Shariat, S. F., Nyírády, P., Rübben, H., & Szarvas, T. (Accepted/In press). Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer. Journal of Urology.